Business
Merck’s COVID-19 pill cuts risk of death, hospitalisation by half in study – Sydney Morning Herald
Merck and partner Ridgeback Biotherapeutics plan to seek US emergency use authorisation for the pill as soon as possible.
Merck & Co Incs experimental oral drug for COVID-19, molnupiravir, reduced by around 50 per cent the chance of hospitalisation or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
Merck and partner…
Continue Reading
-
General13 hours agoIvan Cleary says Panthers trainer Corey Bocking ‘struggling’ after receiving five-match suspension
-
General23 hours agoFlash floods in India wash away village, kill four and leave over 50 missing
-
Noosa News22 hours agoSXSW Sydney Is Hosting a 14-Hour All-Day ‘Freaks and Geeks’ Marathon as Part of Its 2025 Paul Feig Retrospective
-
General22 hours agoIsrael’s war in Gaza faces difficult path forward after release of hostage videos